Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease [Phase 2]

View source ↗

Summary

This is a Phase II randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, efficacy, and pharmacokinetics of Genakumab injection in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis-associated Interstitial Lung Disease
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Genakumab

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD) | Phase 2 | Status: RECRUITING